228 related articles for article (PubMed ID: 27411810)
1. Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.
Cook LM; Araujo A; Pow-Sang JM; Budzevich MM; Basanta D; Lynch CC
Sci Rep; 2016 Jul; 6():29384. PubMed ID: 27411810
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment.
Sato S; Futakuchi M; Ogawa K; Asamoto M; Nakao K; Asai K; Shirai T
Cancer Sci; 2008 Feb; 99(2):316-23. PubMed ID: 18271931
[TBL] [Abstract][Full Text] [Related]
3. An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.
Araujo A; Cook LM; Lynch CC; Basanta D
Cancer Res; 2014 May; 74(9):2391-401. PubMed ID: 24788098
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
5. Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.
Brisset JC; Hoff BA; Chenevert TL; Jacobson JA; Boes JL; Galbán S; Rehemtulla A; Johnson TD; Pienta KJ; Galbán CJ; Meyer CR; Schakel T; Nicolay K; Alva AS; Hussain M; Ross BD
PLoS One; 2015; 10(4):e0123877. PubMed ID: 25859981
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
Dorai T; Dutcher JP; Dempster DW; Wiernik PH
Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
[TBL] [Abstract][Full Text] [Related]
7. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.
Yang J; Fizazi K; Peleg S; Sikes CR; Raymond AK; Jamal N; Hu M; Olive M; Martinez LA; Wood CG; Logothetis CJ; Karsenty G; Navone NM
Cancer Res; 2001 Jul; 61(14):5652-9. PubMed ID: 11454720
[TBL] [Abstract][Full Text] [Related]
10. CD169(+) macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer.
Wu AC; He Y; Broomfield A; Paatan NJ; Harrington BS; Tseng HW; Beaven EA; Kiernan DM; Swindle P; Clubb AB; Levesque JP; Winkler IG; Ling MT; Srinivasan B; Hooper JD; Pettit AR
J Pathol; 2016 Jun; 239(2):218-30. PubMed ID: 27174786
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
12. Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.
Yu-Lee LY; Yu G; Lee YC; Lin SC; Pan J; Pan T; Yu KJ; Liu B; Creighton CJ; Rodriguez-Canales J; Villalobos PA; Wistuba II; de Nadal E; Posas F; Gallick GE; Lin SH
Cancer Res; 2018 Jun; 78(11):2911-2924. PubMed ID: 29514796
[TBL] [Abstract][Full Text] [Related]
13. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
14. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.
Yan Z; Jin S; Wei Z; Huilian H; Zhanhai Y; Yue T; Juan L; Jing L; Libo Y; Xu L
Biochim Biophys Acta; 2014 Sep; 1842(9):1350-63. PubMed ID: 24787381
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.
Sudhan DR; Pampo C; Rice L; Siemann DW
Int J Cancer; 2016 Jun; 138(11):2665-77. PubMed ID: 26757413
[TBL] [Abstract][Full Text] [Related]
16. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo.
Rubin J; Fan X; Rahnert J; Sen B; Hsieh CL; Murphy TC; Nanes MS; Horton LG; Beamer WG; Rosen CJ
Prostate; 2006 Jun; 66(8):789-800. PubMed ID: 16482567
[TBL] [Abstract][Full Text] [Related]
17. Targeting bone physiology for the treatment of metastatic prostate cancer.
Autio KA; Morris MJ
Clin Adv Hematol Oncol; 2013 Mar; 11(3):134-43. PubMed ID: 23598981
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer.
Futakuchi M; Fukamachi K; Suzui M
Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):206-211. PubMed ID: 26656603
[TBL] [Abstract][Full Text] [Related]
20. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
